Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (4,241,312)	$ (1,961,346)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	5,379	$ 339
Amortization of discounts related to convertible notes payable	553,211
Amortization of capitalized financing costs	114,128
Gains on settlement(s) - With former management	(91,710)	$ (1,038,270)
Gains on settlement(s) - With service providers	$ (75,375)	(393,590)
Gains on settlement(s) - Of project advance		(287,809)
Stock-based compensation expense included in - General and administrative expenses	$ 1,727,079	2,864,000
Stock-based compensation expense included in - Research and development expenses	250,787	66,000
Stock-based compensation expense included in - Foreign currency transaction gain	(21,426)	$ (22,772)
(Increase) decrease in -
Grant receivable	48,000
Prepaid expenses	28,012	$ (97,526)
Increase (decrease) in -
Accounts payable and accrued expenses	461,675	241,673
Accrued compensation and related expenses	402,059	(118,084)
Accrued interest payable	81,412	$ 39,044
Unearned grant revenues	(34,333)
Net cash used in operating activities	(792,414)	$ (708,341)
Cash flows from investing activities:
Purchases of equipment	(2,497)	(13,736)
Net cash used in investing activities	(2,497)	$ (13,736)
Cash flows from financing activities:
Proceeds from sale of common stock units	$ 939,710
Proceeds from sale of Series G 1.5% Convertible Preferred Stock		$ 928,500
Proceeds from convertible note and warrant financing	$ 210,000
Proceeds from issuance of note payable to Chairman	40,000	$ 75,000
Principal paid on other short-term notes payable	(21,491)
Repayment of note payable to Chairman	(40,000)	$ (150,000)
Cash payments made for costs incurred in connection with the sale of common stock units	(75,886)
Cash payments made for deferred costs incurred in connection with convertible note and warrant financing	$ (15,700)	$ (20,000)
Cash payments made for costs incurred in connection with sale of Series G 1.5% Convertible Preferred Stock		(92,921)
Net cash provided by financing activities	$ 1,036,633	740,579
Cash and cash equivalents:
Net increase	241,722	18,502
Balance at beginning of period	162,752	14,352
Balance at end of period	404,474	32,854
Supplemental disclosures of cash flow information:
Interest	$ 2,318	$ 102
Income taxes
Non-cash financing activities:
Amortization of deemed dividend on Series G 1.5% Convertible Preferred Stock		$ 10,049,846
Dividends on Series G 1.5% Convertible Preferred Stock	$ 5,880	7,364
Gross exercise price of Series G 1.5% Convertible Preferred Stock placement agent warrants exercised on a cashless basis	4,778	$ 18,689
Gross exercise price of 10% convertible notes payable placement agent warrants exercised on a cashless basis	35,595
Short-term note payable issued in connection with the procurement of director and officer insurance	36,125
Stated value of Series G 1.5% Convertible Preferred Stock converted into common stock	621,038
Fair value of common stock options issued in connection with settlements with former management	26,290	$ 179,910
Fair value of common stock options issued in connection with settlements with service providers	$ 608,064	42,250
Fair value of common stock issued in connection with settlement of project advance		$ 49,000
Fair value of common stock warrants issued to investors in connection with the convertible note and warrant financing	$ 112,557
Fair value of common stock warrants issued to placement agents in connection with the convertible note and warrant financing	12,726
Fair value of beneficial conversion feature of convertible notes payable issued to investors in connection with the convertible note and warrant financing	97,443
Fair value of common stock warrants issued to investors in connection with the extension of the convertible notes	97,188
Fair value of extending common stock warrants issued to investors in connection with the convertible note and warrant financing	180,730
Fair value of beneficial conversion feature of extended convertible notes payable issued to investors in connection with the convertible note and warrant financing	$ 206,689
Fair value of common stock warrants issued to placement agents and selected dealers in connection with the sale of Series G 1.5% Convertible Preferred Stock		$ 443,848
Fair value of common stock warrants issued to placement agents and selected dealers in connection with the sale of common stock units	$ 105,651
Deferred financing costs transferred to additional paid-in capital in connection with sale of Series G 1.5% Convertible Preferred Stock		$ 35,120